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from naive donors. Thus, with a purging procedure, the same
anti-tumor effect was achieved with RLI from tumor-bearing hosts
as from non-tumor-bearing hosts. Allogeneic lymphocyte injection
is a potentially feasible anti-tumor therapy. We therefore com-
pared anti-tumor effects of allogeneic lymphocyte infusion into
naive mice with that of RLI given to mixed chimeras. RLI recip-
ients had longer survival than naive mice receiving allogeneic
lymphocytes. This result suggests not only that the anti-tumor
effect of RLI therapy is stronger than allogeneic lymphocyte infu-
sion therapy but also suggests that rejection of allogeneic cells is
insufﬁcient and mixed chimerism is required prior to the induced
rejection to achieve maximum anti-tumor effects. Conclusion:
Together, these data reinforce the potential of RLI therapy to be
a new HSCT strategy which does not have the risk of graft-versus-
host disease.
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PREVENTION OF GRAFT VERSUS HOST DISEASE BY ANTIBODY MEDI-
ATED DEPLETION OF ACTIVATED DENDRITIC CELLS
Wilson, J.; Rice, A.M.; Hart, D.N.J.; Munster, D.J. Mater Medical
Research Institute, South Brisbane, Queensland, Australia.
The use of haematopoietic stem cell transplantation as a method
of treating leukaemia is signiﬁcantly limited by its major compli-
cation, graft versus host disease (GVHD). Dendritic cells (DCs)
are a haematopoietic population of antigen presenting cells which,
when activated, stimulate donor T lymphocytes. We have pro-
posed, based on preliminary clinical data (Fearnley Blood 1999;93:
728) that DC warrant investigation as an alternative therapeutic
target to prevent GVHD. To investigate the effect of DC deple-
tion in GVHD, we used an established mouse-human chimeric
model of GVHD in which human T lymphocytes are known to be
effector cells. Brieﬂy, conditioned severe combined immunodeﬁ-
cient (SCID) mice were injected with human peripheral blood
mononuclear cells (PBMC), causing a GVHD-like syndrome that
was measured by mouse survival, clinical scoring and human cell
engraftment. Our novel ﬁnding is that human dendritic cells are
required to cause GVHD in this model. Further, by investigating
the role of various human PBMC populations we have shown that
the GVHD process in this model does not involve; a human
anti-mouse antibody component; human CD8 T lymphocytes; or
human CD14 monocytes. Preliminary data have shown that in-
vitro depletion of human DC using the novel antibody, CMRF-44
(Hock Immunology 1994;83:573) increases survival of mice when
compared to mice treated with unmodiﬁed PBMC (p0.064).
Work is underway to assess the effect of in-vivo depletion of human
DC in this model.
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A MURINE TRANSPLANTATION MODEL OF IN VIVO DENDRITIC CELL
DEPLETION TO ATTENUATE GRAFT VERSUS HOST DISEASE
Turner, B.E.; Burns, A.M.; Atkinson, K.; Munster, D.J.; Hart, D.N.J.;
Rice, A.M. Mater Medical Research Institute, South Brisbane, Queens-
land, Australia.
Patient outcome after haemopoietic stem cell transplantation
(HSCT) is governed by time to engraftment, tumour relapse and
development of graft versus host disease (GvHD). Current immu-
nosuppressive strategies for GvHD patients are centred mainly on
manipulation of the effector T-cell; however, new interest in the
possibility of DC depletion is emerging. Our intention is to shift
the focus from elimination of activated T-cells, to controlling the
DCs that activate these T-cells. We have previously shown that
immunoregulatory DC subsets exist in mice and these may be
manipulated in a transplant setting. In addition, we have also
shown one DC subset in particular, the mature plasmacytoid DCs,
to be increased in mouse spleen after conditioning by radiation.
The purpose of this study is to develop novel strategies to deplete
candidate DC subsets in order to control GvHD and improve
outcomes for HSCT recipients. Intra-peritoneal (ip) injection of
N418, a monoclonal antibody against mouse leukocyte integrin
CD11c, or NLDC-145 (DEC-205) is expected to deplete murine
DC in vivo. Dendritic cell depletion by ip injection of N418 cannot
be monitored using a commercial anti-CD11c-APC conjugate due
to epitope blocking. This problem was overcome using a complex
staining matrix of DC markers which include MHCII, 33D1,
DEC205, CD4, CD8a, CD11b, CD45R (B220) and Gr-1 to iden-
tify sub-populations of CD11c. Recent results show up to 50%
depletion of murine DC using these antibodies. The effect of this
on GvHD is being examined.
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USE OF INFLIXIMAB/DACLIZUMAB COMBINATION FOR THE TREAT-
MENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE OF THE
LIVER AND GUT
Rodriguez, V.; Trotz, B.; Anderson, P.M.; Arndt, C.A.S.; Allen, J.;
Khan, S.P. Department of Pediatric and Adolescent Medicine, Division
of Pediatric Hematology-Oncology, Pediatric Blood and Bone Marrow
Transplant Program, Rochester, MN.
We report the use of Inﬂiximab/Daclizumab combination for the
treatment of acute and chronic graft versus host disease (GVHD)
of the liver and gut in two children who failed standard GVHD
therapy. Inﬂiximab was given at a dose of 10 mg/kg weekly 4 and
Daclizumab 1 mg/kg days 1, 4, 8, 15, 22. Patient #1 (Pt) developed
grade 2 chronic GVHD of the liver a year after his third allogeneic
HLA-matched sibling bone marrow transplant (BMT) for relapsed
juvenile myelomonocytic leukemia. Despite immunosuppressive
therapy with FK506, mycophenolate mofetil and prednisone 2
mg/kg/dose, liver enzymes failed to normalize. Within 1 week of
initiation of therapy with Inﬂiximab/Daclizumab, liver enzymes
and bilirubin normalized. Pt #2 developed acute GVHD of the
liver and gut grade 3 day 37 after allogeneic-HLA matched
sibling BMT for Philadelphia positive acute lymphoblastic leuke-
mia. Pt did not show clinical response despite the addition of
prednisone 2 mg/kg/dose to his immunosuppressive regimen. Res-
olution of acute GVHD was observed within two weeks of initia-
tion of Inﬂiximab/Daclizumab. Both patients tolerated the regimen
well with no toxicities and were off immunosuppression 8 and 11
months respectively from the initiation of therapy for GVHD. We
conclude that the combination of Inﬂiximab/Daclizumab seems to
be effective in the treatment of acute and chronic GVHD of the
liver and gut. Future prospective studies in a larger cohort of
patients are needed to conﬁrm this observation.
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GRAFT-VERSUS-HOST DISEASE AFTER NONMYELOABLATIVE HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Na, I.I.; Shn, H.; Song, E.K.; Lee, K.W.; Yoon, S.S.; Lee, J.S.; Park, S.;
Kim, B.K. Seoul National University Hospital, Seoul, Republic of Korea.
Purpose: To evaluate the incidence, severity and response to
therapy of GVHD following NST. Methods: We evaluated ﬁfty-
eight patients transplanted using the ﬂudarabine based condition-
ing regimen between Oct 2000 and Feb 2004; GVHD prophylaxis
was done using cyclosporin (5 mg/kg-3 mg/kg iv or po from day
1 to 90). Patients underwent NST because of old age, comor-
bidities or advanced stage of the disease at the time of transplant.
There were 37 males and 21 females with an age range of 17–66
years (median 48). Results: Incidence of grades II-IV acute
GVHD and chronic GVHD was 34% and 70%, respectively.
Grade 1–2 and 3–4 acute GVHD was observed in 4 and 12
patients, respectively. Chronic GVHD was observed in 23 patients.
11 (70%) and 5 (21%) patients of acute and chronic GVHD
showed no response despite treatment. Cumulative incidence rates
of death with manifestations of GVHD under treatment were 50%
at 15 months. With a median follow-up of 195 days, the 3-year
estimates for overall survival were 32%. Conclusion: The inci-
dence of grade II-IV acute GVHD in Korea may be less than in
Western countries. But acute GVHD responded poorly and
GVHD related death rates were fairly high. Further studies are
needed to improve the eventual outcome not only of acute but also
of chronic GVHD following NST.
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